Keywords: avandia, dominates, debate, ada, conference, cardiovascular, risks
Avandia dominates debate at ADA conference
Article | 02 July 2007
A debate on the cardiovascular risks associated with UK drug major GlaxoSmithKline's popular antidiabetic Avandia (rosiglitazone) continued to dominate the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
